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As many as 16% of adults in the U.S. have genital herpes, which is caused by infection with herpes 
simplex virus 2 (HSV-2). In other parts of the world the prevalence is much higher, with rates as high 
as 80% in parts of sub-Saharan Africa. Besides causing painful genital lesions, HSV-2 infection 
substantially increases the risk of transmitting or acquiring HIV. In populations with high HSV-2 
prevalence, 40–60% of new HIV infections may be attributable to HSV-2. Transmission of HSV-2 is 
known to occur during periodic flare-ups of genital lesions accompanied by viral shedding. However, 
asymptomatic episodes of high viral shedding also occur and likely account for a majority of 
transmission events. Joshua Schiffer, Bryan Mayer, Youyi Fong, David Swan and Anna Wald 
(Vaccine and Infectious Disease Division) set out to pinpoint the threshold amount of HSV-2 copies 
during viral shedding episodes below which HSV-2 transmission is unlikely to occur. To do this, they 
generated a mathematical model that simulates the viral dynamics in HSV-2-positive individuals and 
provides data on the risk of transmission. The study was recently published in the Journal of the 
Royal Society Interface. 
Performing analysis on HSV-2 transmission is difficult due to the fact that episodes of viral shedding 
vary widely in intensity and duration. Furthermore, measuring viral load at time of transmission is not 
feasible, since viral loads can change substantially over several hours. Therefore, Schiffer and 
colleagues utilized known characteristics of the biology of HSV-2 to generate a mathematical model 
in order to simulate viral shedding patterns and estimate risk of transmission. 
In order to create the model simulations, a previous retrospective study of discordant couples was 
utilized to provide data on the median number of sex acts prior to transmission of HSV-2. On 
average, 40 sex acts were required before transmission occurred. This allowed for the calculation of 
a viral infectivity parameter, which directly correlated to the rate of transmission. When entered into 
the model simulations, viral infectivity predicted both the probability of transmission and the viral load 
in the genital tract when transmission events happened. The outcome from the model simulations 
was that an intervention that maintains viral load below 10,000 copies would prevent most if not all 
transmission events. 
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Antiviral medications can reduce viral shedding episodes both in duration and intensity. However, 
HSV-2 transmission from patients on therapy still occurs. Schiffer and colleagues had previously 
shown that this likely stems from the short half-lives of currently available antiviral drugs, resulting in 
periods of sub-therapeutic drug levels, during which the virus is able to actively replicate and achieve 
high viral loads in the genital tract (Schiffer et al., 2013). It is during these periods that transmission 
likely occurs.  
The results from the current study point to the possibility of preventing transmission via the use of 
pharmaceutical interventions able to maintain the viral load below this estimated threshold for 
transmission. "Approximately 10,000 copies of the virus appears to be a good target. If you can get 
shedding below that level at all times you are likely to severely limit or eliminate transmission," said 
Schiffer. 
Current drug regimens are unable to achieve this level, but there are other antiviral medications 
currently coming through the pipeline. A recent study by Dr. Anna Wald and other researchers from 
the Fred Hutchinson Cancer Research Center showed promising results for a new anti-HSV-2 drug, 
pritelivir (Wald et al., 2014). A decrease in viral shedding was observed even when pritelivir was 
administered only once weekly, indicating a longer half-life of the drug than current antiviral 
therapies. Ideally, these clinical trials, together with the mathematical model studies, will ultimately 
lead to successful treatment and prevention for HSV-2 infection and transmission. 
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Image provided by Dr. Joshua Schiffer. 
The proportion of sex acts resulting in transmission according to HSV viral load as generated by 
model simulations with three different degrees of viral infectivity: high (orange), medium (red) and 
low infectivity (blue). 
 
